Risk factors for GIST recurrence were identified , and 2 risk stratification scores were developed using the database of the Scandinavian Sarcoma Group ( SSG ) XVIII trial , where 358 patients with high-risk GIST with no overt metastases were randomly assigned to adjuvant imatinib 400 mg/day either for 12 or 36 months after surgery .